Lipocine (NASDAQ:LPCN) Director John Higuchi Purchases 15,970 Shares of Company Stock
by Scott Moore · The Cerbat GemLipocine Inc. (NASDAQ:LPCN – Get Free Report) Director John Higuchi bought 15,970 shares of the business’s stock in a transaction on Wednesday, September 30th. The stock was purchased at an average price of $2.23 per share, for a total transaction of $35,613.10. Following the purchase, the director directly owned 241,365 shares in the company, valued at approximately $538,243.95. This represents a 7.09% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Lipocine Price Performance
NASDAQ:LPCN traded down $0.13 during trading hours on Thursday, reaching $2.07. 71,208 shares of the stock were exchanged, compared to its average volume of 32,859. The stock has a market cap of $17.06 million, a PE ratio of -1.16 and a beta of 0.40. Lipocine Inc. has a twelve month low of $1.81 and a twelve month high of $12.37. The firm has a 50 day moving average of $2.17 and a 200 day moving average of $2.73.
Lipocine (NASDAQ:LPCN – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.21 million. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. Equities research analysts anticipate that Lipocine Inc. will post -1.54 earnings per share for the current year.
Analyst Ratings Changes
Several equities research analysts have commented on LPCN shares. HC Wainwright reissued a “neutral” rating and set a $4.00 price target on shares of Lipocine in a research report on Monday, September 21st. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Lipocine in a research report on Tuesday, September 22nd. Finally, Weiss Ratings upgraded Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.00.
Check Out Our Latest Research Report on LPCN
Hedge Funds Weigh In On Lipocine
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its position in Lipocine by 57.5% during the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after acquiring an additional 6,982 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in Lipocine in the first quarter valued at $185,000. Exome Asset Management LLC bought a new position in shares of Lipocine in the 1st quarter valued at about $486,000. Persistent Asset Partners Ltd bought a new position in shares of Lipocine in the 4th quarter valued at about $567,000. Finally, Seven Fleet Capital Management LP acquired a new position in shares of Lipocine during the 1st quarter worth about $998,000. 9.11% of the stock is owned by institutional investors.
Lipocine Company Profile
Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.
Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.